Because the ligands of most GPCRs are unknown, assays for their activity generally have no positive controls. GHS-R, however, was known to bind several artificial ligands, such as GHRP-6 or hexarelin, providing a convenient positive control for constructing the assay system used to search for the endogenous ligand. A cultured cell line expressing the GHS-R was established and used to identify tissue extracts that could stimulate the GHS-R, as monitored by increases in intracellular Ca2+ levels. After screening several tissues, very strong activity by an endogenous ligand was unexpectedly found in stomach extracts (). The ligand was finally purified by reversed-phase HPLC (RP-HPLC) and named as ghrelin. The name “ghrelin” is based on “ghre,” a word root in Proto-Indo-European languages for “grow,” in reference to its ability to stimulate GH release. Ghrelin is a 28 amino acid peptide in which the serine 3 (Ser3) is n-octanoylated and this modification is essential for the activity of ghrelin (Fig. 2). Ghrelin is the first known case of a peptide hormone modified by a fatty acid. Rat and human ghrelins differ in only two amino acid residues. There is no structural homology between ghrelin and peptide GHSs such as GHRP-6 or hexarelin.
This peptide is a modified fragment of hGH which contains the portion of the molecule that is believed to be responsible for hGH’s anti-obesity effects. The peptide has been shown to increase fat burning without the increase in blood sugar and growth rate that has been seen with hGH itself. AOD 9604 has been deemed safe for chronic use by the FDA, receiving Human GRAS status in 2014. In addition to its utility as an anti-obesity peptide, AOD 9604 has been shown to have very favorable cartilage repair and regenerative properties, especially when paired with peptide BPC 157.
In February 1997, the National Drugs and Poisons Schedule Committee (NDPSC) decided to reschedule diclofenac dermal preparations (creams) containing 1 per cent or less of diclofenac from Schedule 4 to Schedule 2. This decision was based on the safety profile of a 1 per cent formulation and the then approved indications for use in readily recognised conditions (minor pain relief), which did not include treatment of solar keratosis.

Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
A seminal report by a Merck Research Laboratories group dated 2003 demonstrated for the first time that chronic treatment with GHRP-6 (21 days) prevented sudden death in a canine model of DCM and subsequently subjected to acute myocardial infarction (AMI). In the meantime, the mortality rates for the vehicle and GH-treated groups were about 50%. Although the authors do not precise the mechanism underlying the 100% survival in the GHRP-6 group, an enhanced regional myocardial compensatory function of the nonischemic zone was assumed.40 This notion could be validated at least in part by the fact that the cardiotropic effects shown by GHRP-1, GHRP-2, GHRP-6, and hexarelin in cardiomyocytes and isolated, denervated, perfused hearts are mediated by an elevation of Ca2+ influx through the voltage-gated calcium channel, triggering Ca2+ release from thapsigargin-sensitive intracellular stores, which translated in a positive inotropic response without a chronotropic effect.41 More recent data confirm the ability of hexarelin and other secretagogue peptides that bind and activate the GHS-R1a, to control the cardiac action potential and reduce apoptosis of cardiomyocytes, derived from isolated hearts subjected to ischemia/reperfusion episodes.42
GH’s big USP is its ability to overcome injuries thanks to its restorative properties. Sadly, this notion is still in the firmly in the journal of bro-science. Research in the Clinical Science found when pigs were injected daily with GHRP-6 it had powerful antioxidant effects that could reduce internal heart attack damage. Your DNA isn’t bacon, but it does offer the telltale signs of a potential healing agent and many lifters do report success with restoring long-term overuse injuries, such as tendinitis or rotator cuff niggles. So while beefed up singlet-wearers have sung its praise, the labcoat-wearers haven’t confirmed its scientific efficacy just yet. So watch this space for the new GHRP-6 science that could keep your physique in the sweat game.
For example, if 100mcg more were to be administered after the first 100mcg (making the effective dose of 200mcg), then the second dose will achieve only 50% of what the first dose already did. A 100mcg more (making a total of 300mcg) will achieve only 25% more of the initial dose. This implies that, in order to increase the effect of the compound, only a little more of it can be successfully administered after the saturation dose.
I have not used IGF-1 but I have used a stack of Ipamorelin and CJC 1295 no DAC. I did not do any lab tests before, during or after but definitely noticed increased fat loss and better sleep. I was not trying to increase muscle so there was no change to speak of for me. But you are not recommending their use even without IGF-1, is that correct? I do not compete in anything so WADA is not a concern.
So… now we get down to the individual peptides themselves. I will not go into length with a profile for each one, but instead I will provide two charts that should help in understanding which peptides are GHRH’s and which ones are GHRP’s. Of course, IGF and MGF have their own respective spots but do not have the synergy when combined like GHRP and GHRH.
Phenylephrine is readily eliminated by sulphate conjugation in the intestinal wall, and oxidative deamination by monoamine oxidative glucuronidation in the liver. Monoamine oxidase (MAO) inhibitors can enhance the limited potential of phenylephrine for cardiac and pressor effects, by reducing metabolism. As a largely specific alpha adrenergic drug, with very weak beta agonism, there is little direct cardiac effect. However, in higher doses, there can be increases in both systolic and diastolic blood pressure and a reflex bradycardia. As an adrenergic agonist there is the potential to interact with other sympathomimetic drugs. In overdose phenylephrine can cause hypertension, headaches seizures tachycardia, and vomiting. There has been no evidence from carcinogenicity studies in rodents of any enhanced cancer risk over prolonged exposure.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
This is the most popular variant of IGF-1 that buyers will find on the market today. IGF-1 LR3 comprises 83 amino acids. That means it adds extra 13 amino acids to the sequence of the standard insulin-like growth factor-1. The polypeptide boasts qualities that make it much more powerful than normal IGF-1. It boasts a longer half life of up to 30 hours, compared to the latter’s 15 hours. In addition to bodybuilding, IGF-1 LR3 helps with fat burning, quicker recovery and slowing aging.
Biokey Research TESTO-MAX 20 BRAND: TESTOLONE (RAD140) TESTOLONE (RAD140) Purity : 100% Molecular Formula : C20H16ClN5O2 Molecular Weight: 393.831 CAS#: 1182367-47-0 Description: RAD140 Testolone 30ml @ 20mg per ml Recommended dosage: 0.5-1ml daily DESCRIPTION TESTO-MAX 20 by BioKey Research boasts 20mg/ml of RAD140 which was medically designed to replace testosterone allowing the body to react the same way it would to a healthy dose of the hormone less the…
There is evidence of involvement of organised crime in supply of the substances. The substances are offered for sale via the internet. Many of the substances are promoted as safe alternatives to traditional performance enhancing substances such as the anabolic steroids. Suppliers are making unproven assertions about the efficacy and safety of the substances.
Results: After a single injection of CJC 1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC 1295 was 5.8–8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.

Now these artificially manufactured compounds can replicate certain hormones within the human body to signal or trigger certain effects. Whereas GH (a total protein hormone of 191 amino acids), can attach to receptors at multiple sites within the body to influence different effects (say muscle cells, bone cells and fats cells, to name but three), shorter peptides have been isolated to trigger certain effects in a specific area/s. Imagine it’s like having a full tool box which you can mend a whole car with, but then you take certain tools out for different jobs and keep them apart in separate drawers which do specific jobs…sort of.
Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.

During the last 15 years, a plethora of experimental evidence supports the pharmacological benefits of the exogenous administration of synthetic growth hormone-releasing peptides (GHRPs). In parallel to their growth hormone-releasing action, these agents exert cytoprotective effects encompassing cardiac and extracardiac organs [8]. GHRP-6 is a class of peptidyl GH secretagogue, similar to met-enkephalin, that has reproducibly shown antinecrogenic and antiapoptotic properties in multiple experimental scenarios, including ischemia/reperfusion [9–11]. Globally speaking, exogenously administered GHRP-6 has broadly been shown to act as a prosurvival factor for cells and tissues threatened by otherwise lethal insults.

GH secretagogues differ from exogenous rHGH in their effects primarily because endogenous GH contains all five isoforms of growth hormone, whereas exogenous GH contains only the 20 kilodalton isoform. Different isoforms affect tissues in discreet ways that the 20 kDa isoform cannot. Administration of GH secretagogues causes a pulse-release of GH from the pituitary which is cleared from the body within a few hours. This does not significantly raise plasma insulin-like growth factor 1 (IGF-1) levels.[citation needed]